AI-Enabled Gene Target Prioritization for Obesity Therapy Development
In healthcare and pharmaceutical R&D, selecting the right therapeutic target early can significantly influence the success of an entire development program. This case study shows how Langate helped a pharmaceutical research company prioritize obesity-related gene targets using AI-assisted analysis and integrated biomedical data.
Summary
Langate implemented an AI-powered target prioritization platform that combined genetic evidence, scientific research, and market intelligence into a unified evaluation framework.
Quick Facts
- Timeline: 5 months
- Team: 6 specialists
- Output: 100 candidate genes evaluated
- 12 high-confidence targets prioritized
- 50%+ faster target assessment process
Project Scope
The project included biomedical data integration, machine learning model deployment, and development of interactive dashboards for research teams. The solution was implemented within the client’s secure R&D infrastructure and designed for long-term scalability.
Tech Stack
- Python
- Scikit-learn
- Vertex AI
- Spotfire
Data sources: OpenTargets, GWAS Catalog, ChEMBL, Pharmaproject, PubMed
The Client
The client is a pharmaceutical research organization specializing in metabolic disorders and obesity therapies. Their goal was to identify which candidate genes had the strongest biological rationale and translational potential before moving into preclinical research.
Business Requirements
- Improve efficiency of early-stage target selection
- Reduce uncertainty in prioritization decisions
- Combine scientific and commercial evidence into a unified workflow
- Increase transparency and reproducibility in analysis
- Enable repeatable processes across multiple research programs
The Problem
The research team had identified more than 100 obesity-related gene targets but lacked a consistent method for evaluating them. Manual literature reviews and isolated analytical workflows slowed down prioritization and made investment decisions more difficult.
The Challenges
-
Managing large-scale genetic and biomedical datasets - Ensuring the scientific relevance of AI-generated rankings
- Integrating multiple external data sources into one workflow
- Supporting usability for both scientific and strategic stakeholders
Problems Revealed
The project revealed that the client’s evaluation process depended heavily on disconnected evidence and manual interpretation. This created inconsistencies between teams and limited the ability to compare targets objectively.
The Solution
Achievements
-
Ranked 100 obesity-related candidate genes
-
Identified 12 targets with strong translational support
-
Reduced target evaluation time by more than 50%
-
Improved confidence and consistency in portfolio decisions
The platform enabled the client to shift from hypothesis-driven target selection to a more structured, evidence-based discovery process.
Future Plans
-
The methodology is now being applied across additional metabolic disease programs.
-
Langate continues to support the expansion of the platform toward broader AI-assisted discovery and therapeutic prioritization workflows.
Ready to Accelerate Development With AI?
Send a message to Langate sales
